TELA Bio (TELA) Cash & Equivalents (2018 - 2026)

TELA Bio's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 7.69% year-over-year to $39.5 million in Q1 2026; TTM through Mar 2026 was $39.5 million, a 7.69% decrease from a year earlier, with the FY2025 full-year figure at $50.8 million, down 3.46% from the prior year.
• Cash & Equivalents eased to $39.5 million in Q1 2026 per TELA's latest filing, from $50.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $65.3 million in Q2 2023 and bottomed at $17.3 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $39.5 million (2026), against an average of $40.5 million.
• Across the five-year window, Cash & Equivalents surged 135.4% in 2023 and slumped 70.27% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $42.0 million in 2022, then gained by 11.21% to $46.7 million in 2023, then rose by 12.71% to $52.7 million in 2024, then declined by 3.46% to $50.8 million in 2025, then dropped by 22.23% to $39.5 million in 2026.
• Per Business Quant, the three latest TELA Cash & Equivalents figures stand at $39.5 million (Q1 2026), $50.8 million (Q4 2025), and $29.7 million (Q3 2025).